Trial Profile
A Randomized, Double-blind, Glucagon and Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of SAR438544 Administered by Subcutaneous Route in Healthy Subjects and Patients With Type 1diabetes Mellitus
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs SAR 438544 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Sanofi
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 29 Jul 2016 Status changed from recruiting to discontinued since the company has decided not to pursue the development of SAR438544 in diabetes, according to a Sanofi media release.